Allergy Therapeutics to raise £22 million and CEO to step down
This article was originally published in Scrip
Executive Summary
Allergy Therapeutics plans to raise up to £22.4 million through a new placement, allaying fears about the company's financial position, particularly its debt. The move includes £12.5 million from Azure Ventures, an investment vehicle of the Chile-based Weinstein family, to give it a 40% stake in Allergy.